Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort
Journal of Neurology, Neurosurgery & Psychiatry
Fecha de publicación: 5 de agosto de 2021
Autores: Georgia Peakman, Lucy L Russell, Rhian S Convery, Jennifer M Nicholas, John C Van Swieten, Lize C Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonça, Chris R Butler, Alex Gerhard, Simon DucharmeI, sabelle Le Ber, Fabrizio Tagliavini, Isabel Santana, Florence Pasquier, Johannes Levin, Adrian Danek, Markus Otto, Sandro Sorbi, Jonathan D Rohrer1 Genetic FTD Initiative (GENFI)
DOI: http://dx.doi.org/10.1136/jnnp-2021-326868
Background: Therapeutic trials are now underway in genetic forms of frontotemporal dementia (FTD) but clinical outcome measures are limited. The two most commonly used measures, the Clinical Dementia Rating (CDR)+National Alzheimer’s Disease Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD) and the FTD Rating Scale (FRS), have yet to be compared in detail in the genetic forms of FTD
